29.54
price up icon2.07%   0.60
pre-market  プレマーケット:  29.20   -0.34   -1.15%
loading
前日終値:
$28.94
開ける:
$29.06
24時間の取引高:
875.40K
Relative Volume:
1.12
時価総額:
$1.96B
収益:
$5.79M
当期純損益:
$-199.61M
株価収益率:
-9.814
EPS:
-3.01
ネットキャッシュフロー:
$-188.48M
1週間 パフォーマンス:
-4.15%
1か月 パフォーマンス:
+21.71%
6か月 パフォーマンス:
+29.68%
1年 パフォーマンス:
+47.70%
1日の値動き範囲:
Value
$28.95
$30.14
1週間の範囲:
Value
$28.72
$31.31
52週間の値動き範囲:
Value
$14.40
$31.31

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Name
名前
Celldex Therapeutics Inc
Name
セクター
Healthcare (1106)
Name
電話
908-200-7500
Name
住所
53 FRONTAGE ROAD, HAMPTON
Name
職員
186
Name
次回の収益日
2024-11-04
Name
最新のSEC提出書
Name
CLDX's Discussions on Twitter

Compare CLDX vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CLDX
Celldex Therapeutics Inc
29.54 1.92B 5.79M -199.61M -188.48M -3.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.89 120.48B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
787.50 81.05B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
749.56 46.33B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
327.30 42.26B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.02 32.87B 5.36B 287.73M 924.18M 2.5229

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-10-21 開始されました Mizuho Outperform
2025-10-13 開始されました Barclays Underweight
2025-04-28 開始されました Canaccord Genuity Buy
2025-03-20 開始されました Morgan Stanley Overweight
2025-02-13 開始されました UBS Buy
2024-10-07 開始されました Citigroup Buy
2024-09-30 開始されました Goldman Neutral
2024-09-27 ダウングレード Wolfe Research Outperform → Peer Perform
2024-06-18 開始されました Stifel Buy
2024-06-11 開始されました Wolfe Research Outperform
2023-12-20 開始されました TD Cowen Outperform
2023-11-10 アップグレード Wells Fargo Underweight → Equal Weight
2023-08-22 開始されました Wells Fargo Underweight
2021-09-17 開始されました Jefferies Buy
2021-09-10 開始されました SVB Leerink Outperform
2021-07-22 開始されました Guggenheim Buy
2020-02-21 開始されました Cantor Fitzgerald Overweight
2017-08-01 再開されました H.C. Wainwright Buy
2016-11-07 開始されました Aegis Capital Buy
2016-03-08 ダウングレード Jefferies Buy → Hold
2016-03-07 ダウングレード Guggenheim Buy → Neutral
2016-03-07 ダウングレード Leerink Partners Outperform → Mkt Perform
2016-03-07 ダウングレード Wedbush Outperform → Neutral
2016-03-01 開始されました H.C. Wainwright Buy
2015-08-11 繰り返されました Brean Capital Buy
2015-08-11 繰り返されました Oppenheimer Outperform
2015-08-11 繰り返されました ROTH Capital Buy
2015-06-02 繰り返されました WBB Securities Strong Buy
2014-11-17 繰り返されました ROTH Capital Buy
2014-03-04 繰り返されました Oppenheimer Outperform
2013-07-08 繰り返されました Cantor Fitzgerald Buy
2013-03-08 繰り返されました Cantor Fitzgerald Buy
2013-02-26 繰り返されました Oppenheimer Outperform
2013-01-10 繰り返されました Cantor Fitzgerald Buy
2012-10-02 繰り返されました Oppenheimer Outperform
2012-09-14 繰り返されました Cantor Fitzgerald Buy
すべてを表示

Celldex Therapeutics Inc (CLDX) 最新ニュース

pulisher
08:14 AM

TD Asset Management Inc Decreases Stake in Celldex Therapeutics, Inc. $CLDX - MarketBeat

08:14 AM
pulisher
07:31 AM

Propel Bio Management LLC Makes New $4.01 Million Investment in Celldex Therapeutics, Inc. $CLDX - MarketBeat

07:31 AM
pulisher
Mar 04, 2026

Segall Bryant & Hamill LLC Buys 140,709 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat

Mar 04, 2026
pulisher
Mar 04, 2026

Fisher Asset Management LLC Acquires 104,949 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat

Mar 04, 2026
pulisher
Mar 03, 2026

Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Exploring an 83.57% Potential Upside in Biotech Innovation - DirectorsTalk Interviews

Mar 03, 2026
pulisher
Mar 02, 2026

The Goldman Sachs Group Increases Celldex Therapeutics (NASDAQ:CLDX) Price Target to $34.00 - MarketBeat

Mar 02, 2026
pulisher
Mar 02, 2026

Q3 Earnings Forecast for CLDX Issued By HC Wainwright - MarketBeat

Mar 02, 2026
pulisher
Mar 01, 2026

Celldex Presents Positive Data Demonstrating Barzolvolimab - GlobeNewswire

Mar 01, 2026
pulisher
Feb 28, 2026

Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory - Insider Monkey

Feb 28, 2026
pulisher
Feb 28, 2026

Celldex Stock Pre-Market (-4.7%): Profit-Taking After Positive Phase 2 Data Presentation - Trefis

Feb 28, 2026
pulisher
Feb 28, 2026

Assessing Celldex Therapeutics (CLDX) Valuation After Positive Barzolvolimab Phase 3 Enrollment And Phase 2 Data - Sahm

Feb 28, 2026
pulisher
Feb 27, 2026

Is Celldex Therapeutics (CLDX) Pricing Reflecting Recent 46% One-Year Surge And DCF Upside Potential - Yahoo Finance

Feb 27, 2026
pulisher
Feb 27, 2026

Celldex presents phase 2 data for chronic urticaria treatment By Investing.com - Investing.com Canada

Feb 27, 2026
pulisher
Feb 27, 2026

Celldex Presents Additional Positive Data from Phase 2 - GlobeNewswire

Feb 27, 2026
pulisher
Feb 27, 2026

What is HC Wainwright's Forecast for CLDX Q1 Earnings? - MarketBeat

Feb 27, 2026
pulisher
Feb 26, 2026

CLDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 26, 2026
pulisher
Feb 26, 2026

Celldex Therapeutics (NASDAQ:CLDX) Announces Quarterly Earnings Results - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

Celldex Therapeutics Rallied 24% After Clinical Update: Here’s What Analysts See Next - TIKR.com

Feb 26, 2026
pulisher
Feb 26, 2026

Celldex Therapeutics stock earns 88 RS rating - MSN

Feb 26, 2026
pulisher
Feb 26, 2026

Celldex Therapeutics Hits Day High with 24% Surge in Stock Price - Markets Mojo

Feb 26, 2026
pulisher
Feb 26, 2026

Celldex Therapeutics Hits New 52-Week High at $31.00 - Markets Mojo

Feb 26, 2026
pulisher
Feb 26, 2026

Celldex Therapeutics stock hits 52-week high at 30.66 USD By Investing.com - Investing.com India

Feb 26, 2026
pulisher
Feb 26, 2026

November 20th Options Now Available For Celldex Therapeutics (CLDX) - Nasdaq

Feb 26, 2026
pulisher
Feb 26, 2026

Celldex Therapeutics (NASDAQ:CLDX) Receives Buy Rating from Stifel Nicolaus - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

Celldex Therapeutics (NASDAQ:CLDX) Hits New 52-Week HighHere's What Happened - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Feb 26, 2026
pulisher
Feb 25, 2026

CLDX Technical Analysis & ETF Price Forecast - Intellectia AI

Feb 25, 2026
pulisher
Feb 25, 2026

CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent - Stocktwits

Feb 25, 2026
pulisher
Feb 25, 2026

Celldex Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Celldex: Fourth Quarter Financial Overview - Bitget

Feb 25, 2026
pulisher
Feb 25, 2026

Celldex: Q4 Earnings Snapshot - marketscreener.com

Feb 25, 2026
pulisher
Feb 25, 2026

Celldex Therapeutics stock hits 52-week high at 30.66 USD - Investing.com

Feb 25, 2026
pulisher
Feb 25, 2026

Celldex Therapeutics Opens with a 6.56% Gain, Outpacing S&P 500's 0.69% Increase - Markets Mojo

Feb 25, 2026
pulisher
Feb 25, 2026

Celldex Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update - The Manila Times

Feb 25, 2026
pulisher
Feb 25, 2026

Celldex Therapeutics Hits Day High with Strong 7.91% Intraday Surge - Markets Mojo

Feb 25, 2026
pulisher
Feb 25, 2026

Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q4 Revenue $0.1M, vs. FactSet Est of $1.3M - marketscreener.com

Feb 25, 2026
pulisher
Feb 25, 2026

Celldex Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Feb 25, 2026
pulisher
Feb 25, 2026

Celldex Therapeutics (NASDAQ:CLDX) Sees Strong Trading VolumeStill a Buy? - MarketBeat

Feb 25, 2026
pulisher
Feb 25, 2026

Celldex Therapeutics Completes Enrollment in Phase 3 Studies of Barzolvolimab; Shares Rise - marketscreener.com

Feb 25, 2026
pulisher
Feb 25, 2026

Celldex surges after completing enrollments in late-stage trials for lead asset - Seeking Alpha

Feb 25, 2026
pulisher
Feb 25, 2026

Celldex Therapeutics Completes Enrollment in Phase 3 Studies of Barzolvolimab in Chronic Spontaneous Urticaria - marketscreener.com

Feb 25, 2026
pulisher
Feb 25, 2026

Celldex Completes Enrollment in Global Phase 3 Studies (Embarq-Csu1 and Embarq-Csu2) of Barzolvolimab in Chronic Spontaneous Urticaria - marketscreener.com

Feb 25, 2026
pulisher
Feb 25, 2026

Celldex completes Phase 3 enrollment for CSU treatment ahead of schedule - Investing.com Canada

Feb 25, 2026
pulisher
Feb 25, 2026

Celldex Therapeutics has successfully completed patient enrollment for its two global Phase III clinical studies—Embarq-Csu1 and Embarq-Csu2—of the innovative drug Barzolvolimab for chronic spontaneous urticaria. - Bitget

Feb 25, 2026
pulisher
Feb 25, 2026

Celldex completes enrollment in global Phase 3 studies (Embarq-Csu1 and Embarq-Csu2) of barzolvolimab in chronic spontaneous urticaria - marketscreener.com

Feb 25, 2026
pulisher
Feb 25, 2026

Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria - Yahoo Finance

Feb 25, 2026
pulisher
Feb 25, 2026

Earnings Update: Will FTB PRACL benefit from sector rotationWeekly Market Summary & Expert Approved Trade Ideas - baoquankhu1.vn

Feb 25, 2026
pulisher
Feb 25, 2026

Analysis Recap: How correlated is Celldex Therapeutics Inc to the S P500July 2025 Gainers & Accurate Intraday Trading Signals - baoquankhu1.vn

Feb 25, 2026
pulisher
Feb 25, 2026

Can Celldex Therapeutics Inc disrupt its industryJuly 2025 Price Swings & Stock Market Timing Techniques - baoquankhu1.vn

Feb 25, 2026
pulisher
Feb 24, 2026

Celldex Therapeutics (CLDX) Investor Outlook: Exploring the 119% Potential Upside in Biotech Innovation - DirectorsTalk Interviews

Feb 24, 2026

Celldex Therapeutics Inc (CLDX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$47.43
price down icon 0.11%
$29.52
price up icon 6.00%
$57.80
price up icon 15.99%
$103.80
price up icon 3.02%
$149.88
price up icon 1.96%
biotechnology ONC
$299.02
price up icon 0.67%
大文字化:     |  ボリューム (24 時間):